Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Lipid Absorption

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Lipid-derived Compounds in the Human Body

Lipid-derived Compounds in the Human Body

Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin, delayed...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Socioecological Determinants of Health and the Quality of Colonoscopy in Rural Alabama.

Diseases of the colon and rectum·2024

Same author

Novel Characterization of Socioecological Determinants of Health in Rural Alabama.

The Journal of surgical research·2024

Same author

Routine Intraoperative Use of Esophageal Bougie in Minimally Invasive Hiatal Hernia Repair is Not Necessary.

JSLS : Journal of the Society of Laparoendoscopic Surgeons·2022

Same author

Perceptions of Needlestick Injuries among Medical Students and Residents in the Operating Room.

The American surgeon·2020

Same author

A Comparative Analysis of Factors Associated with Treatment Failure in Uncomplicated Diverticulitis.

The American surgeon·2019

Same author

Bronchomediastinal fistula presenting as purulent pericarditis in a healthy 32-year-old man.

Journal of cardiology cases·2018

Search research articles

Related Experiment Video

Updated: May 24, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Fenofibric acid for hyperlipidemia.

Alok Saurav¹, Manu Kaushik, Syed M Mohiuddin

¹Department of Internal Medicine, Creighton University Medical Center, 601 N 30th Street, Suite 5850, Omaha, Nebraska 68131, USA.

Expert Opinion on Pharmacotherapy

|March 13, 2012

Summary

Fenofibric acid combined with statins effectively treats mixed dyslipidemia. Further research is needed to confirm long-term cardiovascular risk reduction benefits of this combination therapy.

Area of Science:

Cardiovascular Medicine
Pharmacology
Lipid Metabolism

Background:

Statins are primary hyperlipidemia treatments per NCEP guidelines.
The role of fibrates in reducing cardiovascular risk, especially for mixed dyslipidemia, remains debated.
Recent trials like ACCORD have added complexity to understanding fibrate therapy.

Purpose of the Study:

To review fenofibric acid's role in dyslipidemia management.
To analyze recent trial data, including ACCORD, concerning fenofibrate.
To compare fenofibric acid's efficacy and safety against other lipid-lowering agents.

Main Methods:

Literature review of randomized trials on fenofibrate.
Analysis of fenofibric acid's current use in dyslipidemia treatment.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Experiment Videos

Last Updated: May 24, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Comparative assessment of fenofibric acid's efficacy and safety profile.

Main Results:

Fenofibric acid demonstrates effectiveness when used with statins for mixed dyslipidemia.
The combination of fenofibric acid and statins is considered safe.
Long-term cardiovascular risk reduction data for this combination requires further investigation.

Conclusions:

Fenofibric acid with low- to moderate-dose statins is a viable treatment for mixed dyslipidemia.
Further studies are essential to ascertain the long-term cardiovascular benefits.
Fenofibric acid offers an enhanced bioavailability formulation of fenofibrate.